TABLE 5.
Parameter | Variables and findings of:
|
||
---|---|---|---|
Carter et al. (6) | Viscidi et al. (36) | Present study | |
Study population, U.S. State | Female university students, Washington | Female graduate and undergraduate students, Maryland | Female college students, New Jersey |
No. of subjects at baseline | 293 | 376 | 575 |
Mean age (yr [range]) | 19 (18-20) | 22 (18-40) | 20 ± 3a |
HPV DNA data (no. [%]) | |||
Negative | 216 (74) | 247 (66) | 422 (73) |
Positive | 58 (20) | 101 (27) | 132 (23) |
HPV16 DNA positive | 19 (6) | 28 (7) | 21 (4) |
ELISA procedure | |||
Type | Capture, H16.V5 MAb based | Direct | Direct |
Antigen | HPV16 L1 VLP (produced by recombinant vaccinia virus, CsCl purified) | HPV16 L1/L2 VLP (produced by recombinant baculovirus, CsCl purified) | HPV16 L1/L2 VLP (produced by recombinant baculovirus, CsCl purified) |
Antigen concn (ng/well), treatment | NAb | 500, overnight at 4°C | 50, overnight at 4°C |
Blocking agent | 1× PBS-0.05% Tween 20-0.5% nonfat milk | 1× PBS-0.05% Tween 20-0.5% nonfat milk | 1× PBS-0.5% PVA |
Primary antibody dilution | 1:100 | 1:10 | 1:100 |
Detection system | APc-p-nitrophenyl phosphate disodium hexahydrate | HRP-ABTS-H2O2 | HRP-ABTS-H2O2 |
Cutoff OD value | 0.259 | 0.166 | 0.16 |
Subtracted value (definition) | OD of each tested serum reacted with no VLP well | OD of each tested serum reacted with VLP disrupted in carbonate buffer | OD of control human serum reacted with no VLP well (OD = 0.025 to 0.05) |
ELISA results for IgG (%) | |||
Seroprevalence | 9.5 | 24 | 14 |
HPV DNA negative | 6.9 | 19 | 8.7 |
HPV DNA positive | 5.2 | 30 | 23.8 |
HPV16 DNA positive | 52.6 | 46 | 52.4 |
Mean ± standard deviation.
NA, not applicable.
AP, alkaline phosphatase.